Abstract
Acute myeloid leukemia (AML) is a challenging neoplasm that despite therapeutic advances requires efforts to overcome the multidrug resistance (MDR) phenotype, the major cause of relapse. The pterocarpanquinone LQB-118 is a new compound that induces apoptosis in leukemia cells. The objective of this work was to analyze the role of LQB-118 in inhibiting the inhibitor of apoptosis proteins (IAPs), XIAP and survivin, as well as in modulating the subcellular localization of NFκB, in comparison with idarubicin. LQB- 118 was more effective in inducing apoptosis than idarubicin in both AML Kasumi-1 cell line and cells from patients despite their MDR phenotype. LQB-118-induced apoptosis was accompanied by a marked inhibition of IAPs, and cytoplasmatic NFκB subcellular localization. On the other hand, idarubicin increased the IAPs expression and translocated NFκB to the nucleus. The inhibition profile of survivin induced by LQB-118 was comparable to the survivin inhibition profile when we investigated the efficiency of survivin-small interfering RNA (siRNA) treatment. LQB-118 as well as survivin-siRNA contributed similarly to the increase in apoptosis rate of Kasumi-1 cells. The data indicated that there is a functional interaction between the survivin, XIAP and NFκB, which appears to be involved in idarubicin resistance of Kasumi-1 cells. The efficacy of LQB-118 to induce cell death through inhibiting survivin suggests that this IAP may be involved in the chemoresistance phenotype in AML cells. Our findings suggest that LQB-118 might be a promising therapeutic approach for AML patients through survivin downregulation.
Keywords: Acute myeloid leukemia, Chemoresistance, Idarubicin, Inhibitor of apoptosis proteins, NFκB, Pterocarpanquinone LQB-118, siRNA. Survivin, XIAP
Anti-Cancer Agents in Medicinal Chemistry
Title:The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Volume: 13 Issue: 2
Author(s): Flaviana R. de Souza Reis, Fernanda C. Casal de Faria, Carolina P. Castro, Paloma S. de Souza, Flavia da Cunha Vasconcelos, Reinaldo D. Bello, Alcides J. da Silva, Paulo R.R. Costa and Raquel C. Maia
Affiliation:
Keywords: Acute myeloid leukemia, Chemoresistance, Idarubicin, Inhibitor of apoptosis proteins, NFκB, Pterocarpanquinone LQB-118, siRNA. Survivin, XIAP
Abstract: Acute myeloid leukemia (AML) is a challenging neoplasm that despite therapeutic advances requires efforts to overcome the multidrug resistance (MDR) phenotype, the major cause of relapse. The pterocarpanquinone LQB-118 is a new compound that induces apoptosis in leukemia cells. The objective of this work was to analyze the role of LQB-118 in inhibiting the inhibitor of apoptosis proteins (IAPs), XIAP and survivin, as well as in modulating the subcellular localization of NFκB, in comparison with idarubicin. LQB- 118 was more effective in inducing apoptosis than idarubicin in both AML Kasumi-1 cell line and cells from patients despite their MDR phenotype. LQB-118-induced apoptosis was accompanied by a marked inhibition of IAPs, and cytoplasmatic NFκB subcellular localization. On the other hand, idarubicin increased the IAPs expression and translocated NFκB to the nucleus. The inhibition profile of survivin induced by LQB-118 was comparable to the survivin inhibition profile when we investigated the efficiency of survivin-small interfering RNA (siRNA) treatment. LQB-118 as well as survivin-siRNA contributed similarly to the increase in apoptosis rate of Kasumi-1 cells. The data indicated that there is a functional interaction between the survivin, XIAP and NFκB, which appears to be involved in idarubicin resistance of Kasumi-1 cells. The efficacy of LQB-118 to induce cell death through inhibiting survivin suggests that this IAP may be involved in the chemoresistance phenotype in AML cells. Our findings suggest that LQB-118 might be a promising therapeutic approach for AML patients through survivin downregulation.
Export Options
About this article
Cite this article as:
R. de Souza Reis Flaviana, C. Casal de Faria Fernanda, P. Castro Carolina, S. de Souza Paloma, da Cunha Vasconcelos Flavia, D. Bello Reinaldo, J. da Silva Alcides, R.R. Costa Paulo and C. Maia Raquel, The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020019
DOI https://dx.doi.org/10.2174/1871520611313020019 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma
Current Medicinal Chemistry miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Current Medicinal Chemistry Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design G-Quadruplex Interacting Agents Targeting the Telomeric G-Overhang Are More than Simple Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Adeno-Associated Virus-Mediated Gene Transfer in Hematopoietic Stem/Progenitor Cells as a Therapeutic Tool
Current Gene Therapy Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy A Role for SHIP in Stem Cell Biology and Transplantation
Current Stem Cell Research & Therapy Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology In Silico Identification and Analysis of Drug Resistant Mutants of ABL Tyrosine Kinase Based on Detrimental Missense Mutations
Current Signal Transduction Therapy The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Rhein Derivatives, A Promising Pivot?
Mini-Reviews in Medicinal Chemistry Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design